Professor: Dept. of Medical Microbiology/Infectious Diseases, Max Rady College of Medicine, University of Manitoba (1987 –present) and

Coordinator: Antimicrobial Resistance Program, Departments of Medicine and Microbiology, Health Sciences Centre and

Director: Canadian Antimicrobial Resistance Alliance (CARA), Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, CANADA

Dr. Zhanel received his Ph.D. in the Department of Medical Microbiology/Infectious Diseases at the Faculty of Medicine, University of Manitoba and a Doctor of Clinical Pharmacology at the University of Minnesota. He is presently Professor in the Department of Medical Microbiology/Infectious Diseases, College of Medicine; Course Leader, Infectious Diseases Teaching, College of Medicine, University of Manitoba; Coordinator of Antibiotic Resistance in the Departments of Medicine and Clinical Microbiology, Health Sciences Centre; and Research Director of the Canadian Antimicrobial Resistance Alliance (CARA). Dr Zhanel is the founding and Chief Editor of the Canadian Antimicrobial Resistance Alliance (CARA) website (www.can-r.ca).

Dr. Zhanel has published over 1000 papers, chapters and abstracts in the area of antimicrobial resistant infections. He has presented over 1000 lectures as an invited speaker at international, national, and local meetings speaking on the topics of antimicrobial resistant infections as well as treatment and prevention of infectious diseases in Canada, United States, Central and South America, Western and Eastern Europe including Russia, Australia, Southern and Northern Africa, the Middle East and Asia. As research director of the Canadian Antimicrobial Resistance Alliance, Dr. Zhanel's research interests include understanding the prevalence, epidemiology and spread of antimicrobial resistant infections, describing the clinical relevance of resistant infections, identifying and developing rapid diagnostic methods to rapidly diagnose infections, investigating the cellular and molecular mechanisms of resistance, assessing activity of investigational antimicrobials and agents with antimicrobial activity (eg. preservatives, antiseptics, disinfectants, sterilizers) as well as discovering novel antimicrobials (holder of several patents) and assessing the properties, efficacy and biological evolution and influence of select vaccines.

Research using pharmacodynamic modeling and Monte Carlo analyses to provide optimal treatment and prevention of infections is occurring. Both community-acquired and healthcare-acquired infections and pathogens are of interest including respiratory infections (including Streptococcuspneumoniae bacterial infections and influenza virus infections), urinary tract infections, skin/soft tissue infections, intraabdominal infections, nosocomial infections in hospitalized patients as well as in intensive care units, bacteremic infections,Extended spectrum β lactamse (ESBL) producing and carbapenem-resistant Enterobacteriaceae, methicillin-resistant Staphylococcus aureus (MRSA) including community-associated CA-MRSA, vancomycin-resistant enterococci (VRE), Clostridium difficile, Mycobacterium tuberculosis and antifungal resistant infections. Assessing the medical and economic outcomes of infections as well as studying the relationships between antimicrobial usage/stewardship including in dermatology, as well as vaccination and the development of antimicrobial resistant infections is also a priority. Dr. Zhanel has been involved in treatment guideline development for a variety of infectious diseases and is also interested in antimicrobial usage/resistance in humans, animals and food (one health) and the impact of antimicrobial exposure on human and animal microbiomes. Dr. Zhanel has received or been nominated for 55 teaching awards and is a member of the Who’s Who in Medical Sciences Education (WWMSE)